Cain Technology: Withdrawal of the registration application for Recombinant Interferon -2 injection.

Kain Technology announced that the company has recently received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration, agreeing to withdraw the drug registration application for its Recombinant Interferon -2 Injection. Based on the principle of prudence, the company has fully provided for impairment losses related to the development expenses of this project, resulting in a decrease of 111 million yuan in the company's total profit for the year 2025.